Beta Bionics (NASDAQ:BBNX) Stock Rating Upgraded by Baird R W

Beta Bionics (NASDAQ:BBNX) was upgraded by stock analysts at Baird R W to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other research firms have also recently weighed in on BBNX. LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a report on Thursday. They issued a “neutral” rating and a $20.00 price objective for the company. Robert W. Baird began coverage on Beta Bionics in a research note on Thursday. They set a “neutral” rating and a $20.00 target price for the company.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX opened at $20.57 on Thursday. Beta Bionics has a 12 month low of $20.57 and a 12 month high of $24.50.

Insider Activity at Beta Bionics

In other Beta Bionics news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the purchase, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. This represents a 34.46 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mike Mensinger acquired 33,350 shares of the stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, with a total value of $566,950.00. Following the completion of the transaction, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.